Skip to main content

Research News

pharma courses

 

gpat

  • New CAR-T Cell Therapy Shows Promise for Hard-to-Treat Cancers

    Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder for prior CAR-T therapies to detect and fight.
  • UT Health San Antonio develops drug found to more than double survival time for glioblastoma patients

    A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults.

  • New antibodies show potential to neutralize virus that causes COVID-19

    A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep pace with evolving viruses.

  • How aspirin could prevent some cancers from spreading
    The scientists caution that, in some people, aspirin can have serious side effects. Clinical trials are underway to determine how to use it safely and effectively to prevent cancer spread, so people should consult their doctor before starting to take it.
  • Bacteria leaking across stomach lining could indicate risk of gastric cancer, study finds

    A pioneering study has revealed new insights into the role of gastric bacteria in stomach cancer development that could pave the way for a more effective treatment of pre-cancer according to a study published today in Helicobacter.

  • Chronic diseases misdiagnosed as psychosomatic can lead to long term damage

    A ‘chasm of misunderstanding and miscommunication’ is often experienced between clinicians and patients, leading to autoimmune diseases such as lupus and vasculitis being wrongly diagnosed as psychiatric or psychosomatic conditions, with a profound and lasting impact on patients, researchers have found.

  • USFDA accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy®
    Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application for Opdivo nivolumab plus Yervoy ipilimumab as a potential first-line treatment option for adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high MSI-H or mismatch repair deficient dMMR colorectal cancer
  • UM School of Medicine Dermatology Researchers Discover New Skin Disease Using Innovative Diagnostic Platform

    Utilizing a novel diagnostic test for peripheral blood immunophenotyping, researchers were able to identify the specific sources of inflammation triggering the novel skin disease and reverse symptoms with targeted treatments.

    A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no effective treatments beyond symptom management. Now a new study could pave the way for precision-medicine based diagnostic testing and targeted treatment.

  • Hormones may have therapeutic potential to prevent wrinkles, hair graying

    Hormones may be leveraged to treat and prevent signs of aging such as wrinkles and hair graying, according to a new study published in the EndocrineSociety journal Endocrine Reviews.

    Until now, only a limited number of hormones, mainly topical retinoids (retinol and tretinoin) and estrogen which is typically used to treat side effects of menopause, have been used in clinical practice as anti-skin aging compounds. This study reviews a new class of hormones and their anti-aging properties.

  • Research challenges our understanding of cancer predisposition

    New findings question assumptions of cancer formation in individuals with the cancer-predisposition syndrome, neurofibromatosis type 1, and offer hope for a personalised approach to early cancer recognition including for those with similar conditions.

Subscribe to Research News